Guide

如何在药物研发中运用 PBPK 建模与模拟

Learn how PBPK modeling and simulation in drug research and development reduces clinical burden, supports…

Certara2026 年 5 月 12 日

Webinar

Minimize risk when preparing for hepatic impairment studies

Certara2026 年 5 月 12 日

Press Coverage

PBPK Modeling in Pregnancy: Improving Drug Dosing Without Clinical Trials

The FDA is shifting toward approving drugs based on a single pivotal trial supported by…

Certara2026 年 5 月 12 日

Press Coverage

The one-trial era: what the FDA’s shift signals for the future of drug development

The FDA is shifting toward approving drugs based on a single pivotal trial supported by…

Certara2026 年 5 月 6 日

Blog

如何实现药品研发中的动物实验向非动物实验的转型

Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…

Certara2026 年 5 月 5 日

Blog

From models to impact: What QSPC 2026 revealed about the future of drug development

Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…

Certara2026 年 4 月 28 日

Blog

Top 10 benefits of Simcyp® Simulator for drug development

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= 2026 年 4 月 23 日 Physiologically based pharmacokinetic (PBPK) modeling has evolved from an emerging methodology…

Certara2026 年 4 月 23 日

On-Demand Webinar

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Watch this on-demand webinar to learn how the final ICH M15 guidance is shaping Model-Informed…

Certara2026 年 4 月 2 日

On-Demand Webinar

充分发挥 PBPK 模型的全部潜力以加速药物研发

Explore how Novartis applies PBPK modeling in drug development using Simcyp to support regulatory decisions,…

Certara2026 年 3 月 20 日

博客

What are common bioequivalence study mistakes?

Learn about the most common bioequivalence study mistakes drug developers make and the differences between…

Certara2026 年 3 月 20 日

Certara Products – Simcyp

如何在药物研发中运用 PBPK 建模与模拟

Minimize risk when preparing for hepatic impairment studies

PBPK Modeling in Pregnancy: Improving Drug Dosing Without Clinical Trials

The one-trial era: what the FDA’s shift signals for the future of drug development

如何实现药品研发中的动物实验向非动物实验的转型

From models to impact: What QSPC 2026 revealed about the future of drug development

Top 10 benefits of Simcyp® Simulator for drug development

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

充分发挥 PBPK 模型的全部潜力以加速药物研发

What are common bioequivalence study mistakes?

订阅时事通讯

快捷链接

解决方案

联系我们